Therapeutic Target Opportunities

C0989  Regulation of Runx1 for Treatment of Pain (PCT/US2006/007578)
Qiufu Ma, Ph.D.

C1143  A Kinome-Wide Activation of Kinases by Myristoylation (US8178317)
Thomas Roberts, Ph.D. ♦ Jean Zhao, Ph.D.

C1277  Identification of Novel Therapeutic Targets for the Treatment of Metastatic Prostate Cancer (US13011416)
William C. Hahn, M.D., Ph.D.

C1468  Targeting NLRC5 to modulate MHC class I-dependent immune responses in cancer and other diseases (PCT/US2011/043681)
Koichi Kobayashi, M.D., Ph.D.

C1604  Targeting the Glutamine to Pyruvate Pathway for Treatment of Oncogenic KRAS-associated Cancer (PCT/US2013/42468)
Alec Kimmelman, M.D., Ph.D.

C1679  Novel Target YAP1 to Treat Multiple Myeloma and Other Disorders (PCT/IB2013/059908)
Kenneth Anderson, M.D.

C1779  Inhibitors of Histone Deacetylase to Treat Multiple Myeloma (PCT/US2014/064016)
Kenneth Anderson, M.D.

C1832  The PI3K-mTOR-S6K1 Axis Governs Essential 5’UTR-Dependent, eIF4A-Mediated Translation of c-MYC mRNA in MYC-dependent Neoplasia (PCT/US2015/015544)
Jean Zhao, Ph.D.

For more information, please contact the Innovation Office at DFCI:
innovation@dfci.harvard.edu
C1856 Compositions and Methods for Modulating NCOA4-mediated Autophagic Targeting of Ferritin (PCT/US2015/023142)
Alec Kimmelman, M.D., Ph.D.

C1890 ERK1 and ERK2 Mutants that confer Resistance to RAF/MEK or ERK Inhibitors (PCT/US2015/035337)
Levi Garraway, M.D.

C1964 Polymerase Q as a Target in HR-Deficient Cancers (PCT/US2016/057686)
Alan D’Andrea, M.D.

C2149 Compositions and Methods for Screening Pediatric Gliomas (Provisional Filed)
Rameen Beroukhim, M.D., Ph.D.

C2192 Drivers of Endocrine Resistance and Synthetic Lethal Vulnerabilities in Breast Cancer (Provisional Filed)
Xiaole Shirley Liu, Ph.D. • Myles Brown, M.D.

C2253 Inhibition of an Epigenetic Target to Enhance Immune Function in Cancer and Chronic Viral Infections (Provisional Filed)
Kai Wucherpfennig, M.D., Ph.D.